High-risk Medulloblastoma

The high-risk medulloblastoma (HRMB) trial is for patients older than three years.  Around 850 children and young people across Europe will be taking part in this trial.  Each patient will be randomly allocated to different treatments.  We will assess each patient’s quality of life at least twice to see how they are doing during the trial.  The first time will be early on after diagnosis and the second time will be around two years post diagnosis